Sarcomed AB

About Us Sarcomed AB is a biotech company focused on developing treatments for rare muscular dystrophies, holding 14 FDA orphan drug designations. We specialize in advancing repurposed compounds to accelerate patient access to innovative therapies for rare neuromuscular diseases. Products & Services Beyond drug development, Sarcomed provides regulatory consulting services to support biotech companies in navigating complex approval pathways. Our services include: - Orphan Drug Designation (ODD) applications for FDA and EMA - Pre-IND meeting preparation and strategy - Biomarker validation support - CDMO business development freelance services With expertise in regulatory strategy and rare disease drug development, we help bring promising therapies closer to patients in need.